MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Moderna Inc (MRNA) is not a strong buy for a beginner, long-term investor at this time. The stock lacks clear positive momentum, faces significant insider and hedge fund selling, and has weak financial performance. While there are some positive developments in its vaccine pipeline, the overall sentiment and financial outlook suggest holding off on investment until more favorable conditions emerge.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 46.072, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot point of 53.22, with key resistance at 55.581 and support at 50.86. The technicals do not strongly indicate a buy opportunity.
Moderna's Phase 3 trial for its H5 influenza vaccine, backed by $54.3 million from CEPI, could provide long-term growth potential.
Approval of mCOMBRIAX vaccine in the EU enhances its competitive position in the vaccine market.
Hedge funds and insiders are aggressively selling, with insider selling up 89,355.59% in the last month.
Financial performance in Q4 2025 was weak, with revenue down 29.81% YoY and net income at -$826M.
Litigation risks remain, with potential liabilities of up to $1.3B.
Broader market sentiment and CDC controversies could impact vaccine trust and sales.
In Q4 2025, Moderna's revenue dropped 29.81% YoY to $678M, net income fell to -$826M (-26.25% YoY), and EPS declined to -2.11 (-26.99% YoY). However, gross margin improved to 54.57% (+25.51% YoY), indicating cost efficiency.
Analyst ratings are mixed. RBC Capital raised the price target to $35, Barclays to $48, and Piper Sandler to $69, reflecting optimism about vaccine developments. However, BofA maintains an Underperform rating with a $31 target, citing litigation risks and unclear paths for key products. Overall, analysts are cautious with no strong consensus for a buy.
